Trials / Terminated
TerminatedNCT00040404
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 806 (actual)
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CEP-1347 10mg | CEP-1347 10mg, a K252a derivative, retains neuroprotective properties |
| DRUG | CEP1347 25mg | CEP1347 25mg, a K252a derivative, retains neuroprotective properties |
| DRUG | CEP-1347 50mg | CEP-1347 50mg, a K252a derivative, retains neuroprotective properties |
| OTHER | Placebo Comparator | Placebo capsules matching the CEP-1347 capsules |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2002-06-27
- Last updated
- 2012-05-10
Locations
66 sites across 3 countries: United States, Canada, Puerto Rico
Source: ClinicalTrials.gov record NCT00040404. Inclusion in this directory is not an endorsement.